McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal, Canada.
Department of Neurology, National Neuroscience Institute, Singapore.
J Alzheimers Dis. 2018;64(s1):S23-S31. doi: 10.3233/JAD-179924.
Cautious optimism is appropriate for a near future (five years) time frame for a number of drugs acting on the different pathophysiological components of Alzheimer's disease (amyloid deposition, tau hyperphosphorylation, neuroinflammation, vascular changes, to name the most important known so far). Since the relative weight of these components will be different between individuals and will even change over time for each individual, a 'one drug fit for all' approach is no longer defensible. Precision medicine using biomarkers in the diagnosis and treatment of Alzheimer's disease is the new strategy.
对于作用于阿尔茨海默病不同病理生理成分（淀粉样蛋白沉积、tau 过度磷酸化、神经炎症、血管变化，仅列举目前已知最重要的成分）的多种药物，在不久的将来（五年内），谨慎乐观是恰当的。由于这些成分在个体之间的相对权重将不同，甚至对于每个个体而言，随着时间的推移也会发生变化，因此“一种药物适合所有人”的方法已不再合理。使用生物标志物进行阿尔茨海默病的诊断和治疗的精准医学是新策略。
